Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro [63] suggesting that targeting signaling and the FASN axis could be detrimental for cancer cell survival. Here, ERBB2 is linked to osteosarcoma.